These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

992 related articles for article (PubMed ID: 31538491)

  • 1. PROTACs- a game-changing technology.
    Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
    Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
    [No Abstract]   [Full Text] [Related]  

  • 2. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
    Gu S; Cui D; Chen X; Xiong X; Zhao Y
    Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Present and Future of Novel Protein Degradation Technology.
    Xia L; Liu W; Song Y; Zhu H; Duan Y
    Curr Top Med Chem; 2019; 19(20):1784-1788. PubMed ID: 31644408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteolysis-targeting chimeras for targeting protein for degradation.
    Qi J; Zhang G
    Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
    Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
    Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule PROTACs: novel agents for cancer therapy.
    Wan Y; Yan C; Gao H; Liu T
    Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROTACs technology for targeting non-oncoproteins: Advances and perspectives.
    Wang C; Zhang Y; Xing D; Zhang R
    Bioorg Chem; 2021 Sep; 114():105109. PubMed ID: 34175722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges.
    Wang C; Zhang Y; Zhang T; Shi L; Geng Z; Xing D
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1667-1693. PubMed ID: 35702041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Frontiers in the Discovery and Development of PROTACs.
    Barghout SH
    Anticancer Agents Med Chem; 2022 Aug; 22(15):2656-2661. PubMed ID: 35418290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design.
    Mi D; Li Y; Gu H; Li Y; Chen Y
    Eur J Med Chem; 2023 Aug; 256():115444. PubMed ID: 37178483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and pharmaceutical applications of proteolysis-targeting chimeric molecules.
    Liang Y; Nandakumar KS; Cheng K
    Biochem Pharmacol; 2020 Dec; 182():114211. PubMed ID: 32866456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
    Vogelmann A; Robaa D; Sippl W; Jung M
    Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.